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Abstract
Progressive loss of pancreatic β-cell functional mass and anti-diabetic drug responsivity are
classic findings in diabetes, frequently attributed to compensatory insulin hypersecretion
and β-cell exhaustion. However, loss of β-cell mass and identity still occurs in mouse models
of human KATP-gain-of-function induced Neonatal Diabetes Mellitus (NDM), in the absence
of insulin secretion. Here we studied the temporal progression and mechanisms underlying
glucotoxicity-induced loss of functional β-cell mass in NDM mice, and the effects of sodiumglucose transporter 2 inhibitors (SGLT2i) therapy. Upon tamoxifen induction of transgene
expression, NDM mice rapidly developed severe diabetes followed by an unexpected loss
of insulin content, decreased proinsulin processing and increased proinsulin at 2-weeks of
diabetes. These early events were accompanied by a marked increase in β-cell oxidative
and ER stress, without changes in islet cell identity. Strikingly, treatment with the SGLT2
inhibitor dapagliflozin restored insulin content, decreased proinsulin:insulin ratio and
reduced oxidative and ER stress. However, despite reduction of blood glucose, dapagliflozin
therapy was ineffective in restoring β-cell function in NDM mice when it was initiated at >40
days of diabetes, when loss of β-cell mass and identity had already occurred. Our data from
mouse models demonstrate that: i) hyperglycemia per se, and not insulin hypersecretion,
drives β-cell failure in diabetes, ii) recovery of β-cell function by SGLT2 inhibitors is potentially through reduction of oxidative and ER stress, iii) SGLT2 inhibitors revert/prevent β-cell
failure when used in early stages of diabetes, but not when loss of β-cell mass/identity
already occurred, iv) common execution pathways may underlie loss and recovery of β-cell
function in different forms of diabetes. These results may have important clinical implications
for optimal therapeutic interventions in individuals with diabetes, particularly for those with
long-standing diabetes.
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SGLT2 inhibitors protect β-cells from diabetic glucotoxicity

1. Introduction
Reduced pancreatic β-cell function and mass contribute to both type 1 diabetes (T1D) and
type 2 diabetes (T2D) [1]. Reduction of β-cell function is considered an early event, while loss
of β-cell mass occurs closer to clinical manifestation [2–5]. Chronic high glucose induce β-cell
membrane hyperexcitability, persistently elevated intracellular calcium concentration and
insulin hypersecretion, all critically contributing to loss of β-cell mass in diabetes [6–8]. However, loss of β-cell mass still occurs in KATP-gain-of-function (KATP-GOF) mouse model of
human neonatal diabetes mellitus (NDM), in which all of these factors are absent due to KATP
overactivity in pancreatic β-cells [9–13]. Chronic hyperglycemia can also induce β-cell overstimulation, oxidative and endoplasmic reticulum (ER) stress leading to β-cell exhaustion, and
loss of β-cell mass and identity [4, 7, 14–16]. However, most of the studies have been performed in human pancreases from T2D individuals and in animal models of T2D and obesity,
and little is known about mechanisms underlying and temporal progression of loss of functional β-cell mass in monogenic diabetes, in the absence of compensatory increase in insulin
secretion.
Loss of functional β-cell mass in diabetes seems to be independent of the antidiabetic therapy, with most antidiabetic agents initially effective as monotherapy, but failing to reduce
blood glucose over time [17–19], requiring add-on combinational therapies. Sodium glucose
transporter 2 inhibitors (SGLT2i) are a new class of antidiabetic drugs that inhibit glucose
reabsorption in the kidneys and increase glucose excretion in the urine. Because their mechanism of action is independent of insulin secretion or action, SGLT2i can be used in combination with other therapies [20]. T2D individuals treated with SGLT2i demonstrate improved
glycemic control, increased glucose- and incretin-stimulated insulin secretion and enhanced
insulin sensitivity as well as reduced blood pressure, decreased plasma lipids and reduced risk
for cardiovascular events [21–24]. Db/db and ob/ob mouse models of T2D and obesity treated
with SGLT2i (luseogliflozin, ipragliflozin or dapagliflozin) demonstrate reduced blood glucose,
augmented insulin and GLP-1 secretion, increased β-cell mass, β-cell replication and α- to βcell conversion, and restored β-cell identity [25–30]. Moreover, db/db mice with SGLT2 deletion show improved insulin sensitivity, increased β-cell proliferation and decreased β-cell
death [31]. Streptozotocin-induced diabetic mice treated with empagliflozin demonstrate
increased insulin mRNA, serum insulin, and β-cell area and proliferation [32]. Although
improved β-cell function by SGLT2i has been suggested in humans and rodents, the underlying mechanisms and timeframe of this effect remain elusive, with most studies performed in
the setting of obesity and T2D. Here we determined the underlying mechanisms and temporal
progression to β-cell failure and established the effects of SGLT2i therapy in an insulin secretory-deficient mouse model of KATP-GOF induced NDM.

2. Materials and methods
Mouse models
Neonatal diabetic mice were generated as previously described [9]. Briefly, mice expressing
Kir6.2 (K185Q,ΔN30) mutant transgene under the Rosa26 locus promoter were crossed with
tamoxifen-inducible Pdx-Cre mice, to generate transgenic mice expressing the NDM mutation
in β-cells. To induce transgene expression, 12 to14-week old mice were injected with five consecutive daily doses of tamoxifen (50 μg/g body weight). Littermate single transgenic (Rosakir6.2, Pdx-cre) were also injected with tamoxifen and used as controls since to date, no significant differences in phenotype were found. Both male and female mice were used for all experiments as no significant sex-based differences were found. Mice were maintained on a 12-hour
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light/dark cycle. Animals were housed in BJCIH animal facility with a 24hs surveillance with
veterinarian and personnel assigned to the facility. Power analysis determined the sample size,
and it is stated in each experimental design and figures. Experimental groups were randomized, and treatment separation was assigned.

Ethics statement
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was
approved by the Washington University School of Medicine Animal Care and Use Committee
(IACUC, Protocol Number: 19–1078). Tissue collection was performed at the end of the experiments at a predetermined time, with the animals euthanized by inhalation of Isoflurane in a
chamber, and then cervical dislocation. All efforts were made to minimize suffering.

Plasma hormones, and blood and urine glucose measurements
Blood glucose was measured either randomly or after an overnight fast as indicated by using
the one-touch Bayer Contour T5 glucometer (Mishawaka, IN). Plasma insulin and glucagon
levels were quantified using a rat/mouse insulin and mouse glucagon ELISA (Crystal Chem,
IL). Urine glucose was analyzed by glucose-Autokit (Wako Diagnostics, Richmond, VA).
Plasma lipids were measured by Washington University Diabetes Research Center Metabolic
Tissue Function Core (http://diabetesresearchcenter.dom.wustl.edu/diabetes-modelsphenotyping-core/). For all in vitro analyses, at least three independent animals were used.
Cells and tissues from each animal were kept separated and analyzed individually. Data collection was stopped at predetermined, arbitrary time as 10 days after initiation of DAPA/vehicle
treatment. No data were excluded. Further methods details are available in the following sections or in the Supplementary Materials section.

Glucose Tolerance Tests (GTT) and Insulin Tolerance Tests (ITT)
GTTs and ITTs were performed after overnight or six-hour fast, respectively. Blood glucose
was measured before (time 0) and after (15, 30, 45, 60, 90 and 120 min) intraperitoneal (ip)
injection of 1.5 mg/kg dextrose (GTT) or 0.5 U/kg human insulin (ITT, HI-210 Lilly).

Pancreatic islet isolation
For islet isolation, euthanized mice were perfused through the bile duct with Hank’s solution
containing collagenase type XI (Sigma, St. Louis, MO). Pancreases were removed, digested for
11 minutes at 37˚C in a water bath, hand shaken, and washed in cold Hank’s solution. Islets
were handpicked under a stereo microscope in RPMI (11mM glucose) media (ThermoFisher
Scientific) supplemented with fetal calf serum (10%), penicillin (100 U/ml), and streptomycin
(100 μg/ml). For all assays involving islets, freshly isolated islets were immediately processed
and frozen at -80C to avoid changes induced in the absence of DAPA.

Insulin and proinsulin content measurement
Total insulin and proinsulin content were measured using rat/mouse insulin ELISA kit (Crystal Chem, IL) and proinsulin ELISA kit (Mercodia, Uppsala, Sweden) respectively from
batches of ten size-matched islets after acid-ethanol extraction [12].
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Quantitative PCR analysis
Islet RNA extraction and qPCR analysis was performed as described previously [10]. Primers
used to determine ER stress markers [33] and mature islet cell markers [10] have been
published.

Western blot analysis
15μg of total protein lysate was loaded per lane. Blots were incubated overnight with the following antibodies: Beta-actin (1:1000; EMD Millipore, MO cat #MAB1501R), Proinsulin
(1:1000; CST, MA, cat #3014S), TXNIP (1:1000; MBL International, MA, cat #K0205-3),
sXBP1 (1:1000; Santa Cruz Biotechnology, TX, cat #sc-7160), BiP (1:1000, CST cat #3183),
Prohormone convertase 1/3 (1:1000; CST, MA, cat #11914), Prohormone convertase 2
(1:1000; CST, MA, cat #14013T), SERCA2b (1:1000, Santa Cruz Biotechnology, TX, cat #SC8095). Blots were washed and probed with RDye infrared fluorescent dye-labeled secondary
antibody conjugates (1:10,000; LI-COR biotechnology). Fluorescence intensity was determined by image studio Lite (LI-COR biotechnology). Raw uncropped western blot images can
be found at https://figshare.com/search?q=10.6084%2Fm9.figshare.17161070.

Immunohistochemical and morphometric analysis
Pancreases from control and NDM mice were fixed in 10% NBF, and paraffin-embedded after
serial dehydration for sectioning. Four- to eight mice from each genotype were sampled on
5μm thick sections, 25μm apart (spanning the whole pancreas) and used for immunohistochemical/morphometric analysis. For morphometric analysis, at least 3 pancreatic sections
from 3–8 mice from each genotype were covered systematically by accumulating images from
non-overlapping fields on an inverted EXC-500 fluorescent microscope (Visual Dynamix,
Chesterfield, MO). Hematoxylin-Eosin (HE) staining was carried out as described previously
[10]. Briefly, slides were stained with rabbit anti-insulin (1:100 CST cat#C27C9) and mouse
anti-glucagon (1:100, Abcam cat#ab10988) antibodies and their distribution visualized using
secondary antibodies conjugated with AlexaTM 488 or AlexaTM 594 (Molecular Probes,
Eugene-OR) using an EXC-500 fluorescent microscope (Visual Dynamix, Chesterfield, MO).
Whole pancreatic area and islet area were determined by H&E staining, and β-cell area and
intensity by insulin staining (as above). Β-cell mass was calculated as the product of relative βcell area to whole pancreatic area and pancreatic weight for each mouse.

Reactive oxygen species
Islets were dispersed into single cells using Accutase (Sigma-Aldrich). They were plated in
RPMI complete media overnight on ploy-D-lysine (Sigma-Aldrich) coated glass-bottom culture dishes (MatTek Corp). After overnight culture, cells were incubated in KRB containing
2.8 mM glucose for one hour, followed by 16.7 mM glucose for one hour at 37˚C. In the last 30
minutes of incubation, CellROX Deep Red Reagent (final concentration of 5μM, Molecular
Probes ThermoFisher Scientific, MA) and live nuclear reagent (Hoeschst 33342, Molecular
Probes) were added. After 30 min, cells were washed with PBS 3 times and imaged using a
Leica DMI 4000B inverted microscope (Lecia microsystems, IL). Fluorescence intensity was
quantified by image studio Lite (LI-COR biotechnology).

Calcium measurements
The genetically encoded calcium sensor pRSET-RcaMP1h was a gift from Loren Looger
(Addgene plasmid # 42874). The coding sequence of the RcaMP1h sensor was subcloned into
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the pShuttle vector, and recombinant adenovirus particles were produced following the
AdEasy XL Adenoviral Vector System protocol (#240010 Agilent Technologies). Islets were
transduced using a microfluidic device to obtain uniform infection of the islet cells throughout
the islet volume and were incubated overnight before imaging. Imaging on islets was performed on the LSM880 inverted microscope (Zeiss Inc), using a heated stage-top incubator
(Pecon GmbH) 24 hours post transduction. Islets were imaged in KRBH medium (NaCl 128.8
mM, KCl 4.8 mM, KH2PO4 1.2 mM, MgSO4 1.2 mM, CaCl2 2.5 mM, NaHCO3 5mM,
HEPES 10 mM, pH 7.40, 0.1% BSA) supplemented with the desired glucose concentration.
RcaMP1h fluorescence was excited with a 561 nm laser, and the emission was collected
through a 570–650 nm bandpass.

Dapagliflozin treatment
NDM, db/db and ob/ob mice were randomly separated into two treatment groups–vehicle or–
Dapagliflozin (DAPA, SelleckChem, Houston, TX), a sodium-glucose transporter 2 inhibitor.
DAPA was suspended in vehicle containing 30% Polyethylene glycol, 5% Propylene glycol,
0.4% tween-80 as recommended by the manufacturer. Twelve to fourteen- week-old NDM
mice were injected with 5 consecutive doses of tamoxifen to induce diabetes. Mouse groups
were assigned randomly, and the study was not blinded. On day 7 after tamoxifen injection,
NDM mice received a daily oral gavage of either vehicle or DAPA (10 mg/kg of body weight)
for 10 days. Eleven-week-old db/db and ob/ob mice also received a daily oral gavage of either
vehicle or DAPA (10 mg/kg of body weight) for 10 days. Vehicle and DAPA treated mice were
monitored through blood glucose measurements daily and blood serum collection and then
euthanized for ex vivo analysis. Data collection was stopped at predetermined, arbitrary time
as 10 days after initiation of DAPA/vehicle treatment. No data were excluded. Further methods details are available in the following sections or in the Supplementary Materials section.

Statistical analysis
Data are presented as mean ± standard deviation of the mean. Statistical differences between
two groups were determined using Student’s t-test and among several groups were tested
using analysis of variance (ANOVA) with Tukey’s post-hoc test in GraphPad PRISM version
8.0 (La Jolla, CA). We performed normality tests and the compared datasets were normally
distributed and had similar variability. Significant differences among groups with � p<0.05,
��
p<0.01; ��� p<0.001 and ���� p<0.0001 are indicated in the Figures, and non-significant differences are not shown. The sample size, n, indicates the total number of biological samples.

3. Results
Early loss of insulin content and proinsulin accumulation in islets from
insulin secretory-deficient NDM mice
As expected, upon induction of KATP-GOF expression by tamoxifen, NDM mice developed
severe diabetes and a marked decrease in plasma insulin levels (Fig 1A and 1B) [9]. As predicted by the ‘switch off’ of glucose-stimulated insulin secretion, NDM mice showed significantly impaired glucose tolerance (Fig 1C and 1D). Unexpectedly however, and not explained
by expression of the KATP mutation, insulin content was markedly reduced (>50%) at day 15
of diabetes (Fig 1E), correlating with decreased insulin immunostaining (Fig 1F). This was
accompanied by a significant increase in plasma proinsulin (Fig 1G), islet proinsulin protein
levels (Fig 1H) and proinsulin:insulin content ratio (Fig 1I). Prohormone convertases 1/3 and
2, which direct the endoproteolytic cleavage of proinsulin to insulin and C-peptide, were
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Fig 1. Loss of insulin content precedes loss of β-cell mass and identity in NDM (A) Non-fasting blood glucose and (B)
Plasma insulin over time (n = 15–20 mice/group). Glucose tolerance test at day 7 (C) and 15 (D) post tamoxifen
induction (n = 11–13 mice/group). (E) Total islet insulin content per 10 islets at different days post tamoxifen
induction (n = 8–10 mice/group). (F) β-cell intensity determined in pancreatic sections immunostained with insulin
(n = 8 mice/group, 3 slides from each mouse). (G) Plasma proinsulin at day 15 post tamoxifen induction (n = 7–8
mice/group). (H) Western blot analysis of proinsulin protein, representative (top) and quantification (bottom) on
islets at day 15 post tamoxifen induction (n = 6 mice/group). (I) Proinsulin:insulin ratio at day 15 post tamoxifen
induction (n = 10 mice/group) measured by Elisa. (J) Western blot analysis of prohormone convertases 1/3 and 2,
representative (top) and quantification (bottom) on islets at day 15 post tamoxifen induction (n = 4 mice/group). (K)
Calcium imaging, representative (left) and quantification (right) at 2- and 16-mM glucose at day 15 post tamoxifen
induction (n = 6 mice/group, scale-bar = 100μm). Black = controls and green = NDM. Data are expressed as
mean ± SD. Significant differences �� P<0.01, ��� P<0.001, ���� P<0.0001.
https://doi.org/10.1371/journal.pone.0258054.g001
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significantly decreased in NDM islets (Fig 1J), suggesting reduced proinsulin processing as a
potential cause for increased proinsulin. As expected by the presence of overactive KATP-channels in β-cells, NDM islets at 15 days of diabetes did not demonstrate an increase in cytosolic
calcium in response to high glucose (Fig 1K), confirming previous results in islets from longstanding diabetic NDM mice [13].

Increased oxidative and ER stress in islets from NDM diabetic mice
Proinsulin biosynthesis accounts for ~50% of total protein synthesis of β-cells, placing a high
secretory demand on the ER where proinsulin undergoes its initial folding [34]. Accumulation
of proinsulin in β-cells generally indicates activation of the ER stress pathway [35]. Islets from
NDM mice demonstrated a significant increase in message RNA levels in the ER stress markers BiP, spliced XBP1 (sXBP1), Atf4 and Atf6, and no changes in Chop (Fig 2A). Protein levels
of sXBP1, a product of the IRE pathway that is critical in highly secretory cells to maintain cell
stress homeostasis, was significantly increased in NDM islets (Fig 2B), and ER based ATPase
sarco/endoplasmic reticulum calcium pump 2 (SERCA2b) significantly reduced (Fig 2C).
Reactive oxygen species (ROS) formation (Fig 2D) and thioredoxin-interacting protein
(TXNIP, a pro-oxidant protein) (Fig 2E), were also markedly increased in NDM islets at day
15 of diabetes, suggesting increased oxidative stress in early stages of diabetes. Islets are particularly susceptible to oxidative damage due to low levels of antioxidants enzymes. Correlating
with this, glutathione peroxidase and catalase were not detected, and superoxide dismutase 2
(SOD2) was not altered in NDM islets (Fig 2F). Interestingly, despite the decrease in insulin
content at day 15 of diabetes, islet morphology, insulin and glucagon staining were not affected
(Fig 3A) in NDM islets. Moreover, total islet area, percent of β-cell area and β-cell mass
(Fig 3B) as well as the β-cell identity markers insulin, Pdx1, Nkx6.1 and Glut2 (Fig 3C) were
not altered in NDM islets. In addition, plasma glucagon did not significantly change during
diabetes progression (Fig 3D), and percent of α-cell area and gene expression of the α-cell
marker Arx remained similar in NDM and littermate controls islets at day 15 of diabetes
(Fig 3E and 3F).

Dapagliflozin therapy restores insulin content in non-obese NDM mice
through reduction of β-cell stress
To determine whether reducing blood glucose reverts loss of insulin content and cellular
stress, twelve-week old NDM mice were treated with the SGLT2i dapagliflozin (DAPA) on day
7 after tamoxifen injection. As expected, DAPA-treated NDM mice showed a significant
reduction in blood glucose over time (Fig 4A), and increased urinary glucose output (Fig 4B),
with no changes in plasma insulin (Fig 4C) or body weight (Fig 4D) after 10 days of DAPA
therapy compared to vehicle-treated NDM. Plasma lipids such as triglycerides (TG), cholesterol, and free fatty acids (FFA) did not change by DAPA treatment (Fig 4E). DAPA-treated
NDM mice showed lower fasting glucose (Fig 4F), and improved glucose tolerance (Fig 4G)
with a significant reduction in the area under the curve (AUC, Fig 4H), and a mild, but not significant, improvement in insulin sensitivity (S1A Fig) compared to vehicle-treated NDM mice.
Ten days of DAPA treatment was sufficient to increase insulin content (Fig 4I), reduce proinsulin (Fig 4J) and proinsulin:insulin ratio (Fig 4K), with no significant changes in the prohormone convertases PC1/3 and PC2 (S1B Fig) compared to vehicle-treated NDM mice.
Importantly, islets from DAPA-treated NDM mice showed a significant decrease in sXBP1
and Atf4 message RNA levels (Fig 4L), and a marked reduction in TXNIP and sXBP1 protein
levels (Fig 4M), suggesting decreased cellular stress as underlying recovery of β-cell function in
NDM. No differences in any of the above-mentioned tests were observed in control mice
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Fig 2. NDM islets demonstrated oxidative and ER stress in early diabetes (A) Quantitative real-time PCR analysis of
gene expression of ER stress markers in islets (n = 7–9 mice/group). Western blot analysis of (B) sXBP1 and (C)
SERCA2b, representative blot (top) and quantification (bottom) (n = 6 mice/group). (D) Reactive Oxygen Species
(ROS) measurement in dispersed islets; representative images (left) and quantification (right) (n = 18 images from
islets obtained from 3–4 mice in each group; scale bar = 25 μm). (E) Representative western blot of TXNIP (top) and
quantification (bottom) (n = 6 mice/group). Samples were run on the same gel but were not contiguous. (F)
Representative western blot of SOD2 (top) and quantification (bottom) (n = 6 mice/group). Black = controls and
green = NDM at day 15 post tamoxifen induction. Data are expressed as mean ± SD Significant differences � P<0.05,
��
P<0.01, ��� P<0.001, ���� P<0.0001.
https://doi.org/10.1371/journal.pone.0258054.g002

treated with vehicle or DAPA (Fig 4A–4K). To test if alleviation of cellular stress is a unique
effect of dapagliflozin or an effect of lowering blood glucose, NDM mice were implanted with
low dose slow-release insulin pellets (0.1U/day/pellet) 7 days post tamoxifen, to match the
timeline for DAPA therapy (S1 Text). While blood glucose was significantly reduced (S2A
Fig), total islet insulin content higher (S2B Fig) and proinsulin:insulin ratio reduced (S2C Fig)
in insulin-treated NDM mice compared to placebo-treated mice, cellular stress marker proteins such as TXNIP and sXBP1 were not improved (S2D Fig), suggesting unique effects of
DAPA on reducing β-cell stress.
Notably however, despite the significant decrease in blood glucose levels over time and 10
days after treatment (Fig 5A and 5B), total insulin content (Fig 5C) was not improved in islets
from NDM mice when therapy was initiated at >42 days of diabetes. These results suggest
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Fig 3. No changes in morphology or β-cell identity in islets from NDM mice at early stages of diabetes (A)
Representative images of islets immunostained with insulin (green) and glucagon (red). (B) Islet area (left), Percent of
β-cell area (middle) and β-cell mass (right) at day 15 of diabetes (n = 8 mice/group, 3 slides from each mouse). (C)
Quantitative real-time PCR analysis of gene expression of mature β-cell identity markers in islets (n = 5–8 mice/group)
at day 15 of diabetes. (D) Plasma glucagon over time during development and progression of diabetes. (E) Percent of
α-cell area (n = 8 mice/group, 3 slides from each mouse), and (F) Quantitative real-time PCR analysis of gene
expression of the α-cell identity marker Arx in islets at day 15 of diabetes (n = 4 mice/group). Black = controls and
green = NDM at day 15 post-tamoxifen injection. Data are expressed as mean ± SD.
https://doi.org/10.1371/journal.pone.0258054.g003

inability of SGLT2i to improve β-cell function in animals with long-standing diabetes when
they had already lost β-cell mass and identity.

Dapagliflozin therapy reduced cellular stress in mouse models of obesity
and T2D
Animal models of obesity and T2D diabetes such as leptin receptor deficient db/db and leptin
deficient ob/ob mice were also treated with DAPA (S1 Text). DAPA-treated db/db mice
showed a marked reduction in blood glucose (S3A Fig), no significant changes in plasma insulin or plasma lipid levels (S3B and S3C Fig), and a significant increase in insulin content and
decrease in TXNIP and sXBP1 protein levels (S3D and S3E Fig) compared to vehicle treated
db/db mice. Similarly, ob/ob mice treated with DAPA showed reduction in blood glucose,
although less consistent compared to the other two mouse models (S4A Fig), no significant
changes in plasma insulin or plasma lipids (S4B and S4C Fig), and an increase in islet insulin
content and decrease in XBP1 and TXNIP protein levels (S4D and S4E Fig) compared to vehicle-treated ob/ob mice.
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Fig 4. Dapagliflozin therapy in NDM mice improves β-cell function though reduction of oxidative and ER stress (A)
Blood glucose in control and NDM mice administered with vehicle or dapagliflozin (DAPA) by daily oral gavage on
day 7 post-tamoxifen (n = 5–15 mice/group). (B) Urine glucose (C) Plasma insulin and (D) % body weight change
after 10 days of vehicle or DAPA treatment (n = 5–11 mice/group). (E) Plasma lipid panel (TG, cholesterol and FFA)
(n = 5–9 mice/group). Fasting blood glucose (F), glucose tolerance test (G) and calculated area under the curve (AUC,
H) from control and NDM mice after 10-day treatment with vehicle or DAPA (n = 5 mice/group). (I) Islet total insulin
content, (J) Total proinsulin content and (K) Proinsulin:insulin ratio (n = 5–12 mice/group). (L) Quantitative realtime PCR analysis of gene expression of ER stress markers in islets after 10 days treatment with DAPA or vehicle (n = 4
mice/group). (M) Western blot analysis on isolated islets after 10 days treatment with DAPA or vehicle, representative
blot (top) and quantification (bottom) of TXNIP and sXBP1 (n = 4–6 mice/group). Black open circles: control vehicle,
pink open circles: control DAPA, grey filled circles and grey bars: NDM vehicle treated, and pink filled circles and pink
bars: NDM DAPA treated mice. Arrow indicates initiation of DAPA therapy. Data are expressed as mean ± SD
�
P<0.05, �� P<0.01, ��� P<0.001, ���� P<0.001 (For Fig 4A significance of ��� P<0.001, ���� P<0.001 respect to all other
three groups, and # p<0.0001 respect to control vehicle and control DAPA only).
https://doi.org/10.1371/journal.pone.0258054.g004
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Fig 5. Dapagliflozin therapy does not improve insulin content in long-standing NDM NDM mice treated with vehicle
or DAPA, starting on day 42 post-tamoxifen (A) Blood glucose over time and (B) plasma glucose 10 days after
treatment (n = 6 mice/group). (C) Total islet insulin content 10 days after treatment with vehicle or DAPA (n = 6
mice/group). Grey = vehicle-treated NDM and pink = DAPA-treated NDM mice. Arrow indicates initiation of DAPA
therapy. Data are expressed as mean ± SD � P<0.05, �� P<0.01, ��� P<0.001, ���� P<0.001.
https://doi.org/10.1371/journal.pone.0258054.g005

4. Discussion
Loss of pancreatic β-cell mass and identity, and increased apoptosis have been demonstrated
in T2D and T1D individuals [1, 3, 5, 36], and in animal models of monogenic diabetes as well
as T1D and T2D diabetes [2, 4, 10, 11, 37]. Beta-cell oxidative and ER stress has been shown to
be involved in β-cell failure in both T1D and T2D [36]. We demonstrated here that this is also
the mechanism underlying early loss of insulin content in a mouse model of monogenic KATPGOF induced NDM in the absence of hyperglycemia-induced insulin hypersecretion and βcell exhaustion. Decreased insulin content and prohormone convertases, and increased proinsulin and cellular stress are early events in NDM. Decreased prohormone convertases could
contribute to the backlog of proinsulin to insulin conversion with proinsulin accumulation,
but they could also be a consequence of diminished ER efficiency thus contributing to a vicious
cycle. These early changes occurred in the absence of loss of β-cell mass and identity, which is
observed in long-standing diabetes. These results are in agreement with similar mechanisms of
β-cell failure and loss of functional β-cell mass that occur in humans and mouse models of
both T1D and T2D/obesity [36, 38, 39], thus highlighting common execution pathways for βcell failure in different forms of diabetes.
Although some studies demonstrated that treatment with SGLT2i preserved β-cell mass in
ZDF rats [40], streptozotocin-induced T1D mice [32] and in db/db and ob/ob mouse models
of obesity and T2D [25–30, 41], the underlying mechanism of this protection remains elusive.
Reduced insulin content and increased intracellular proinsulin [42], as well as increased Atf4
and Chop message RNA and sXBP1 protein levels [43, 44] in islets from db/db mice also suggest increased ER stress in T2D/obesity. We demonstrate here for the first time that SGLT2i
therapy increased islet insulin content, and decreased proinsulin levels through reduction in
β-cell oxidative and ER stress in mouse models of monogenic NDM and obese/T2D. Our demonstration of lack of restoration of insulin content in NDM mice treated with DAPA at day 42
of diabetes correlate with no improvements in insulin biosynthesis/secretion in 16 week old
db/db mice treated with luseogliflozin [25], and with absence of preservation of β-cell function
in 15–20 week old db/db mice treated with dapagliflozin [28]. This suggests that there is a
point of no return for improvement of islet function by SGLT2i, when β-cells had already lost
their mature identity. These studies also correlate with those demonstrating that dapagliflozin
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was effective as monotherapy at early stages of human T2D, but only as add-on mediation to
other antidiabetic drugs in individuals with long-standing diabetes [45].
In addition to the effect of lowering blood glucose, SGLT2i also act as insulin-sensitizing
agents. While some T2D individuals showed an improvement in insulin sensitivity, reduced
HbA1c and weight loss by SGLT2i therapy [46], others did not [47]. Obese db/db mice treated
with empagliflozin [41, 48], and db/db mice with genetic deletion of SGLT2 [31] demonstrated
improved insulin sensitivity. However, lack of significant changes in insulin sensitivity and
lipid profile in 10-day DAPA-treated NDM mice suggests additional effects of SGLT2i in insulin-resistant/obese states. However, longer SGLT2i therapy could lead to a reduction in plasma
lipids and therefore additional improvements in β-cell function as it has been shown in mouse
models of obesity/T2D [49–51].
Increased ER stress and decreased insulin signaling might synergistically reduce β-cell function [52–54], which is supported by our data demonstrating restoration of insulin signaling
and reduction of ER stress by DAPA therapy. However, insulin therapy was able to preserve
insulin content and decrease proinsulin:insulin ratio in NDM mice, which is consistent with
proinsulin synthesis not being regulated by insulin autocrine feedback on β-cells [54], but it
was unable to reduce ER stress. Therefore, we speculate that synergistic effects might be
induced by a combination of SGLT2i and insulin therapy, which could explain the beneficial
effects of combination of these two agents in individuals with long-standing T2D [45]. In db/
db mice, treatment with a combination of DPP-4 inhibitor and SGLT2 inhibitor exerted more
beneficial effects on β-cell mass, function and maintenance of β-cell identity markers in early
(7-week old) than the advanced (16-week old) phase of diabetes [55].
In conclusion, our study showed increased β-cell oxidative and ER stress as contributing
factors that underlie early loss of insulin content in insulin secretory-deficient monogenic
NDM, and that reduction of oxidative and ER stress by SGLT2i, restores insulin content and
β-cell function. The mechanism underlying these effects was also demonstrated in mouse
models of obesity and T2D, suggesting common pathways for recovery of functional β-cell
mass in different forms of diabetes. This paradigm shift in understanding additional actions of
SGLT2i correlate with the reduction of β-cell stress in NDM islets by DAPA, but not by insulin
therapy. Apart from the glucose-lowering effects of SGLT2i, clinical trials revealed cardiac and
renal protective effects in non-diabetic patients. The beneficial effects of SGLT2i treatment
emerged from the DAPA-Heart Failure (HF) trial, in which reduction of HF and mortality
was independent of reduction of hemoglobin A1C, and also from use of SGLT2i in experimental models of HF, in which cardiac improvements were independent of diabetes/hyperglycemia
[56, 57]. Moreover, accumulating preclinical studies demonstrate the therapeutic benefits of
SGLT2i as powerful antioxidants in human diseases [58]. Thus, we may re-conceptualize the
role of SGLT2i as organ-protective agents, including the endocrine pancreas in this study, by
promoting adaptive cellular reprogramming of stressed cells for survival and function [59, 60].
From a therapeutic perspective, our study strongly supports the use of SGLT2i as monotherapy
in initial stages to preserve functional β-cell mass in monogenic diabetes, and as add-on combinational therapy to other antidiabetic agents in long-standing diabetes.

Supporting information
S1 Text. Animals and treatments. For insulin treatment, NDM mice were randomly separated and implanted with low-dose insulin (0.1U/day/implant, LinBit, Canada) or placebo pellets at day 7 after tamoxifen induction, as previously described [10], and blood glucose was
monitored daily as in Materials and Methods. Data collection was stopped at predetermined,
arbitrary time as 10 days after initiation of Insulin treatment. In addition, we tested the effect
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of DAPA in mouse models of obesity and type-2 diabetes. No data were excluded. Mice homozygous for the obese spontaneous mutation, Lepob (B6.Cg-Lepob/J) (https://www.jax.org/
strain/000632) as well as mice for the leptin receptor mutation (BKS.Cg-Dock7m+/+ Leprdb/
J) (https://www.jax.org/strain/000642) were obtained from The Jackson Laboratory. Mouse
groups were assigned randomly, and the study was not blinded. Vehicle and DAPA treated
mice were monitored through blood glucose measurements and blood serum collection, and
then euthanized for ex vivo analysis. For all in vitro analyses, at least three independent animals
were used. Cells and tissues from each animal were kept separated and analyzed individually.
Data collection was stopped at predetermined, arbitrary time as 10 days after initiation of
DAPA/vehicle treatment. No data were excluded.
(PDF)
S1 Fig. Insulin tolerance and prohormone convertases in NDM mice treated with vehicle or
DAPA (A) Insulin tolerance test from control and NDM mice after 10-day treatment with
vehicle or DAPA, calculated as percentage from the initial blood glucose at 6-hrs fast (n = 5
mice/group). (B) Representative blot (top) and quantification (bottom) of prohormone convertases PC1/3 and PC2 (n = 4 mice/group). Black open circles: control vehicle, pink open circles: control DAPA, grey filled circles and grey bars: NDM vehicle treated, and pink filled
circles and pink bars: NDM DAPA treated mice. Data are expressed as mean ± SD.
(PDF)
S2 Fig. Insulin therapy in NDM mice reduces blood glucose but does not improve islet cellular
stress (A) Blood glucose levels in NDM mice with subcutaneously implanted insulin (0.1U/
day/implant) or placebo pellets for 10 days, beginning at day 7 post tamoxifen (n = 5–6 mice/
group). (B) Total insulin content, (C) Proinsulin to insulin ratio (n = 6 mice/group), and (D)
Western blot analysis, representative blots (left) and quantification (right) (n = 3–4 mice/
group) on islets isolated from NDM mice after 10 days of insulin or placebo treatment. Grey
bars and dots = placebo-treated NDM mice and purple bars and dots = Insulin-treated NDM
mice. Data are expressed as mean ± SD. Significant differences � P<0.05, �� P<0.01.
(PDF)
S3 Fig. Dapagliflozin therapy reduced cellular stress in Db/db mice. (A) Blood glucose in
db/db mice treated with vehicle or DAPA (n = 6 mice/group). (B) Plasma insulin and (C)
Plasma lipids (triglycerides, cholesterol and FFA) in db/db mice after 10 days of vehicle or
DAPA treatment (n = 6 mice/group). (D) Insulin content and (E) Western blot analysis, representative blot (top) and quantification (bottom), on islets from db/db mice 10-days DAPA or
vehicle treated (n = 6 mice/group). Arrow indicates initiation of DAPA or vehicle treatment.
Data presented as mean ± SD. Significant differences � p<0.05, �� P<0.01, ���� p<0.0001. Grey
= db/db vehicle-treated and blue = db/db DAPA-treated mice.
(PDF)
S4 Fig. Dapagliflozin therapy reduced cellular stress in Ob/ob mice. (A) Blood glucose in
ob/ob mice treated with vehicle or DAPA (n = 6 mice/group). (B) Plasma insulin and (C)
Plasma lipids (triglycerides, cholesterol and FFA) in ob/ob mice 10-days vehicle or DAPA
treated (n = 6 mice/group). (D) Insulin content and (E) Western blot analysis, representative
blot (top) and quantification (bottom), on islets from ob/ob mice 10-days after DAPA or vehicle treatment (n = 6 mice/group). Arrow indicates initiation of DAPA or vehicle treatment.
Data represent mean ± SD. Significant differences � p<0.05, �� P<0.01, ���� p<0.0001. Grey =
ob/ob vehicle-treated and orange = ob/ob DAPA-treated mice.
(PDF)
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